Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
Cadrenal Therapeutics (Nasdaq: CVKD) announced on December 1, 2025 the immediate appointment of Lee Scott Golden, M.D., as an independent member of its Board of Directors.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cadrenal Therapeutics (Nasdaq: CVKD) announced on December 1, 2025 the immediate appointment of Lee Scott Golden, M.D., as an independent member of its Board of Directors. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics and has over 25 years of industry experience across cardiovascular and hematologic drug development.
His background includes senior medical roles at Espero BioPharma and Gemphire, leadership at Pfizer, Actelion, Eisai, and Mesoblast, and advisory work in coagulation sciences. Management highlighted his expertise in late-stage clinical development and regulatory pathways as aligned with Cadrenal’s goal to advance tecarfarin and its broader anticoagulation pipeline.
Details
News Market Reaction – CVKD
On Dec 1, the day this news came out, CVKD closed 4.13% below the previous close.
Data tracked by StockTitan Argus for the Dec 1 session.
Key Figures
- Industry experience
- 25 years
- Dr. Golden’s biopharma and cardiovascular drug development background
Historical Context
-
Added experienced independent director focused on cardiovascular and hematologic drugs.
-
Q3 2025 loss and limited cash alongside clinical and acquisition updates.
-
Participation in Lytham Partners conference and investor outreach efforts.
-
Acquisition of eXIthera Factor XIa inhibitors expanding anticoagulation portfolio.
-
Q2 2025 results showing higher net loss and evolving trial plans.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
anticoagulation therapy medical
thrombosis medical
cardiac rhythm control medical
hematologic medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director.
Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT), where he leads global clinical development across a broad rare disease pipeline. Before joining PTC, Dr. Golden served as the Chief Medical Officer at Espero BioPharma, Inc., a development-stage cardiovascular pharmaceutical company focused on developing drugs for unmet needs in thrombosis and cardiac rhythm control, and as Chief Medical Officer at Gemphire Therapeutics, Inc. He also serves as Chairman of the Advisory Board for Coagulation Sciences LLC. Previously, Dr. Golden held senior roles at Pfizer, Actelion, Eisai, Mesoblast, and others, with a long-standing focus on cardiovascular and hematologic drug development.
“We are delighted to welcome Dr. Golden to our Board,” said Quang X. Pham, Chairman and Chief Executive Officer of Cadrenal Therapeutics. “Lee’s deep experience in late-stage clinical development, particularly in cardiovascular medicine and anticoagulation, is highly aligned with our mission to deliver safer, more predictable anticoagulant options for patients with significant unmet needs. His track record in guiding therapies through clinical development and regulatory pathways will be invaluable as we continue to advance tecarfarin and our broader pipeline.”
“Cadrenal Therapeutics is working in an area of high clinical importance, where better anticoagulation options could meaningfully impact outcomes for patients with complex cardiovascular conditions,” said Dr. Golden. “I look forward to working with the Board and the leadership team to help guide the Company’s strategy and clinical programs as we seek to bring differentiated therapies to patients and create value for shareholders.”
Dr. Golden has more than 25 years of industry experience, with increasing responsibilities, managing global, cross-functional teams responsible for creating and deploying strategic and clinical development plans. He has extensive experience across multiple therapeutic areas and with orphan diseases. Dr. Golden received a B.S. from the University of Michigan and an MD from New York University School of Medicine, where he also completed his Internal Medicine residency. He then completed Fellowships in Cardiology at the University of Miami and Interventional Cardiology at George Washington University Hospital, where he also served as an adjunct instructor.
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a biopharmaceutical company with a mission to develop novel and differentiated biopharmaceutical products that bridge critical gaps in current acute and chronic anticoagulant therapy. We bridge these gaps by developing novel and differentiated anticoagulants, or blood thinners, designed to provide greater predictability, increased stability, more precise control, and fewer bleeding complications. We currently have two clinical-stage assets: tecarfarin, an oral vitamin K antagonist (VKA) for chronic use, and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. By targeting underserved patient populations and advancing therapies designed for both chronic and acute use, we aim to reshape standards of care in anticoagulation. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.
Safe Harbor
Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding developing transformative therapeutics to overcome current gaps in anticoagulation therapy, the expected contribution of Dr. Golden and continuing to advance tecarfarin and the Company’s broader pipeline. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to develop transformative therapeutics to overcome current gaps in anticoagulation therapy, Dr. Golden’s ability to help guide the Company’s strategy and clinical programs, the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.
For more information, please contact:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.